Prime Research

Latest Research

Biosimilar strategy for infliximab by MedDrive™ includes the reference drug

The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab) in April of 1998 for the treatment of Crohn’s disease. It was…

Read More

Drug Pipeline Quarterly Update: December 2021

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA…

Read More

Biosimilar strategy for rituximab using MedDrive™

Rituxan® (rituximab) from Genentech was first approved by the FDA in 1997 for treatment of non-Hodgkin’s lymphoma. It went on to receive FDA approval for…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …